• For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy.

• Evidence of adequate organ function as determined by all of the following:

‣ Absolute neutrophil count (ANC) \>1000/µL without growth factor support within 7 days prior to start of first study intervention

⁃ Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention

⁃ Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method

⁃ Total bilirubin ≤1.5 × upper limit of normal (ULN); for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN

⁃ Aspartate transaminase (AST) ≤3 × ULN or alanine transaminase (ALT) ≤3 × ULN; in participants with documented liver metastases, AST or ALT ≤5 × ULN

⁃ Alkaline phosphatase (ALP) ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN

⁃ Oxygen saturation \>90% on room air

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

• Presence of measurable disease by RECIST, v1.1 assessed within 28 days prior to start of first study intervention.

• Presence of baseline safely accessible lesions of adequate size for on-treatment biopsies (exceptions for lesion size may be granted with medical monitor approval) and participant willingness to undergo protocol prescribed on-treatment biopsies.